Abstract: A multifunction peripheral includes a color number conversion determiner. The color number conversion determiner determines whether it is appropriate to perform either an index color process or a full-color process based on a color distribution degree, which is a distribution degree of pixel values of the respective sets of pixel data included in input image data, a photograph area ratio, which is a ratio of photograph area pixel data forming a photograph area to the pixel data, and a color uniformity area ratio, which is a ratio of white base area pixel data forming a white base area to the pixel data.

Abstract: A developing device contact and separation mechanism includes a monochrome operating member, a color operating member, and a rotating member that rotates among a first position for a non-operational state, a second position for color printing, and a third position for monochrome printing. At the first position, the rotating member moves the monochrome developing device to the separated position, via the monochrome operating member, and the color developing device to the separated position, via the color operating member. At the second position, the rotating member moves the monochrome developing device to the contacting position, via the monochrome operating member, and the color developing device to the contacting position, via the color operating member. At the third position, the rotating member moves the monochrome developing device to the contacting position, via the monochrome operating member, and the color developing device to the separated position, via the color operating member.

Abstract: Provided is a non-transitory computer-readable storage medium storing a program causing a computer to execute a process, the process including: receiving a first operation that specifies a person symbol from a plurality of person symbols representing persons present in a family tree; displaying a plurality of first candidate person symbols capable of being connected with the person symbol specified by the received first operation by referring to a first storage unit that stores attribute information with respect to each of a plurality of persons; receiving a second operation that selects a first candidate person symbol from the plurality of first candidate person symbols that have been displayed; and displaying the first candidate person symbol selected by the received second operation while the selected first candidate person symbol is being connected with the person symbol specified by the first operation.

Abstract: Provided is a non-transitory computer-readable storage medium storing a program causing a computer to execute a process, the process including: receiving a first operation that specifies a person symbol from a plurality of person symbols representing persons present in a family tree; displaying a plurality of first candidate person symbols capable of being connected with the person symbol specified by the received first operation by referring to a first storage unit that stores attribute information with respect to each of a plurality of persons; receiving a second operation that selects a first candidate person symbol from the plurality of first candidate person symbols that have been displayed; and displaying the first candidate person symbol selected by the received second operation while the selected first candidate person symbol is being connected with the person symbol specified by the first operation.

Abstract: The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method.

Abstract: An antiproliferative effect of IFN-? gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-? to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect of the invention relates to targeting the characteristic genetic aberration, K-ras point mutation, in pancreatic cancer, and that the expression of antisense K-ras RNA significantly suppresses the growth of pancreatic cancer cells. When these two gene therapy strategies are combined, the expression of antisense K-ras RNA significantly enhanced IFN-?-induced cell death (1.3-3.5 fold), and suppressed subcutaneous growth of pancreatic cancer cells in mice. The invention also relates to a method of suppressing pancreatic cancer cells using double strand RNA formed by antisense and endogeneous K-ras RNA in combination with the anti-tumor activity of IFN-?.

Abstract: Methods of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding a human IFN-alpha and operably linked to a promoter, and the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence, wherein the antisense K-ras nucleotide sequence is operably linked to a promoter, and the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppress growth of pancreatic tumor or cancer cells in the mammal.

Abstract: The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method.

Abstract: An antiproliferative effect of IFN-? gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-? to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect of the invention relates to targeting the characteristic genetic aberration, K-ras point mutation, in pancreatic cancer, and that the expression of antisense K-ras RNA significantly suppresses the growth of pancreatic cancer cells. When these two gene therapy strategies are combined, the expression of antisense K-ras RNA significantly enhanced IFN-?-induced cell death (1.3-3.5 fold), and suppressed subcutaneous growth of pancreatic cancer cells in mice. The invention also relates to a method of suppressing pancreatic cancer cells using double strand RNA formed by antisense and endogeneous K-ras RNA in combination with the anti-tumor activity of IFN-?.

Abstract: A deletion type mutein of heparin-binding secretory transforming factor (hst-1) possesses excellent cell growth promoting activity and is stable. The present mutein can therefore be used as a therapeutic medicine such as a healing promoter for burns, wounds, surgical injuries etc.